CIK 0001501989
- Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 273521219
- Phone
- +1 650-515-3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Option exercise CEO acquired 109,768 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale General Counsel sold 5,268 shares at $2.09 ($10,986)
- 4 Open-market sale CEO sold 20,223 shares at $2.09 ($42,175)
- 4 Open-market sale SVP, Finance and Accounting sold 2,971 shares at $2.09 ($6,196)
- 4 Open-market sale SVP, Chief Scientific Officer sold 12,795 shares at $2.09 ($26,684)
- 4 Open-market sale Chief Business Officer sold 6,562 shares at $2.09 ($13,685)
- 4 Grant or award CEO acquired 90,000 shares (grant or award)
- 4 Grant or award General Counsel acquired 25,000 shares (grant or award)
- 4 Grant or award SVP, Finance and Accounting acquired 40,000 shares (grant or award)
- 4 Grant or award Chief Business Officer acquired 30,000 shares (grant or award)
- 4 Grant or award SVP, Chief Scientific Officer acquired 26,250 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 26,250 shares (grant or award)
- 4 Open-market sale CEO sold 13,551 shares at $1.38 ($18,710)
- 4 Open-market sale SVP, Chief Scientific Officer sold 4,077 shares at $1.38 ($5,628)
- 4 Open-market sale Chief Business Officer sold 4,077 shares at $1.38 ($5,628)
- 4 Open-market sale General Counsel sold 4,077 shares at $1.38 ($5,629)
Page 4 of 20 · 400 filings